Extra COVID Shots Improve Antibody Strength in MS Patients

Credibility

Interest

Key Takeaway

For people with MS on anti-CD20 therapy, getting three or four COVID-19 vaccine doses made their antibodies work better even if the amount stayed low.

What They Found

The study looked at people with MS who take anti-CD20 medicines that lower some immune cells and measured their COVID antibodies after two, three, or four shots. The number of patients with any detectable antibodies rose a little from about half after two shots to about two-thirds after four shots. Importantly, among those who did have antibodies, the quality got much better: more antibodies bound tightly (this is like Velcro sticking more strongly) after more shots. Also, neutralizing antibodies that can block the Omicron BA.2 variant were rare after two shots but became common after four shots in those who had antibodies. Finally, COVID-specific T cells (another part of the immune system that helps fight infection, like backup soldiers) were found in over 92% of patients after two or more shots, showing a strong cellular response despite the medicine that lowers some antibody-producing cells.

Who Should Care and Why

People with MS who are treated with anti-CD20 medicines should care because these treatments can make it harder to make antibodies, and more vaccine doses improved how well antibodies work. Caregivers and family members should know that extra vaccine doses may give better protection, especially against variants like Omicron, even if tests still show low antibody levels. Healthcare providers can use this information to recommend additional vaccine doses and to explain that antibody strength can rise even if the total amount looks low. This matters for daily life because better-quality antibodies can reduce the chance of getting sick or having severe illness, similar to upgrading from a weak umbrella to one that actually keeps you dry in heavier rain. People deciding about boosters can weigh that extra doses may help the team of immune defenses, not just the antibody count alone.

Important Considerations

The study had relatively small groups, especially for people who got four shots, so results might change in larger studies. It focused on one variant (Omicron BA.2) and specific lab tests, which do not guarantee full protection in the real world. These findings do not prove that every person will avoid infection, but they show improved antibody quality and strong T cell responses after more vaccine doses.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Vaccination Clinical Trials

Article Topics:

COVIDMultiple sclerosisSARS-CoV-2disease-modifying therapiesimmunologyvaccine

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News